renalytix.com (RNLX): Bathi resik saben saham (EPS TTM)

Renalytix Plc (RNLX) revenues are based on the implementation of AI tests in nephrology and the expansion of insurance coverage. The company's net income per share over 12 months clearly confirms the dynamics of financial flows, where -0.62 becomes the new value of the indicator. Patents and FDA approval create a defensive barrier, although high scientific competition in CKD diagnostics forces the company to constantly optimize the cost of its solutions.
Rincian analitis lan laporan data perusahaan Renalytix Plc (RNLX)

Investors must weigh the asset's current yield against its financial stability risks. This metric reflects the annual net profit per share, excluding the impact of share issuance. By analyzing the TTM fundamental earnings per share trend, one can assess the real efficiency of the business. For Renalytix Plc (RNLX), this trend is critical due to supply chain vulnerabilities and regulatory barriers in biopharmaceuticals. The upward trajectory confirms the company's ability to overcome geopolitical complexities.